Logo

Ionis Initiates P-III CORE Study of Olezarsen for the Treatment of Severe Hypertriglyceridemia

Share this

Ionis Initiates P-III CORE Study of Olezarsen for the Treatment of Severe Hypertriglyceridemia

Shots:

  • The company initiates second P-III CORE study to evaluate olezarsen vs PBO in patients with severe hypertriglyceridemia who are on the currently available SoC therapies for elevated triglycerides
  • The 1EPs of the study is the percent change in fasting triglycerides from baseline @6mos. The 2EPs include percent change from baseline in triglycerides @12mos. & in other atherogenic lipids @6 & 12mos. & the proportion of patients who achieve fasting triglycerides =500/880/1000 mg/dL
  • In P-II clinical study, olezarsen met its 1EPs & 2EPs i.e., reductions in triglyceride & apoC-III levels, favorable safety & tolerability profile, 91% of patients achieved a normal triglyceride level of <150 mg/dL

  | Ref: PR Newswire | Image: Wikipedia

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions